Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Mar. 22, 2019 | Jun. 30, 2018 | |
Document Information [Line Items] | |||
Entity Registrant Name | BioCardia, Inc. | ||
Entity Central Index Key | 0000925741 | ||
Trading Symbol | bcda | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Emerging Growth Company | false | ||
Entity Small Business | true | ||
Entity Common Stock, Shares Outstanding (in shares) | 43,631,684 | ||
Entity Public Float | $ 27,400,314 | ||
Entity Shell Company | false | ||
Document Type | 10-K | ||
Document Period End Date | Dec. 31, 2018 | ||
Document Fiscal Year Focus | 2018 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Current assets: | ||
Cash and cash equivalents | $ 5,358 | $ 12,689 |
Accounts receivable, net of allowance for doubtful accounts of $9 and $6 at December 31, 2018 and 2017, respectively | 274 | 95 |
Inventory | 141 | 191 |
Prepaid expenses | 445 | 340 |
Total current assets | 6,218 | 13,315 |
Property and equipment, net | 145 | 169 |
Other assets | 54 | 54 |
Total assets | 6,417 | 13,538 |
Current liabilities: | ||
Accounts payable | 1,020 | 902 |
Accrued expenses and other current liabilities | 1,528 | 1,263 |
Deferred revenue | 167 | |
Total current liabilities | 2,548 | 2,332 |
Deferred rent | 77 | 81 |
Total liabilities | 2,625 | 2,413 |
Stockholders’ equity: | ||
Preferred stock, $0.001 par value, 25,000,000 shares authorized as of December 31, 2018 and 2017; no shares issued and outstanding as of December 31, 2018 and 2017 | ||
Common stock, $0.001 par value, 100,000,000 shares authorized as of December 31, 2018 and 2017; 43,611,240 and 38,218,660 shares issued and outstanding as of December 31, 2018 and 2017, respectively | 43 | 38 |
Additional paid-in capital | 90,110 | 83,537 |
Accumulated deficit | (86,361) | (72,450) |
Total stockholders’ equity | 3,792 | 11,125 |
Total liabilities and stockholders’ equity | $ 6,417 | $ 13,538 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Allowance for doubtful accounts | $ 9 | $ 6 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 25,000,000 | 25,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 43,611,240 | 38,218,660 |
Common stock, shares outstanding (in shares) | 43,611,240 | 38,218,660 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Revenue: | |||
Total revenue | $ 625 | $ 479 | $ 576 |
Costs and expenses: | |||
Cost of goods sold | 517 | 690 | 746 |
Research and development | 8,453 | 5,799 | 3,330 |
Selling, general and administrative | 5,757 | 6,395 | 4,108 |
Total costs and expenses | 14,727 | 12,884 | 8,184 |
Operating loss | (14,102) | (12,405) | (7,608) |
Other income (expense): | |||
Interest income | 118 | 95 | |
Interest expense | (1,736) | ||
Change in fair value of convertible preferred stock warrant liability | 250 | ||
Change in fair value of maturity date preferred stock warrant liability | 10 | ||
Change in fair value of convertible shareholder notes derivative liability | (1,224) | ||
Other expense | (3) | 2 | (2) |
Other income (expense), net | 115 | 97 | (2,702) |
Net loss | $ (13,987) | $ (12,308) | $ (10,310) |
Net loss per share, basic and diluted (in dollars per share) | $ (0.36) | $ (0.32) | $ (1.23) |
Weighted-average shares used in computing net loss per share, basic and diluted (in shares) | 38,377,606 | 38,160,543 | 8,368,284 |
Product [Member] | |||
Revenue: | |||
Total revenue | $ 282 | $ 389 | $ 517 |
Collaboration Agreement [Member] | |||
Revenue: | |||
Total revenue | $ 343 | $ 90 | $ 59 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands | Restricted Stock Units (RSUs) [Member]Preferred Stock [Member]Convertible Preferred Stock [Member] | Restricted Stock Units (RSUs) [Member]Common Stock [Member] | Preferred Stock [Member]Convertible Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2015 | 110,500,514 | 1,578,962 | |||||
Balance at Dec. 31, 2015 | $ 46,030 | $ 2 | $ 358 | $ (49,832) | $ (3,442) | ||
Exchange of convertible preferred stock warrants to common stock (in shares) | 10,807 | ||||||
Exchange of convertible preferred stock warrants to common stock | 25 | 25 | |||||
Reclassification of convertible shareholder notes derivative liability | 2,268 | 2,268 | |||||
Conversion of convertible notes into common stock (in shares) | 8,091,103 | ||||||
Conversion of convertible notes into common stock | $ 8 | 12,148 | 12,156 | ||||
Conversion of preferred stock into common stock (in shares) | (110,500,514) | 9,208,376 | |||||
Conversion of preferred stock into common stock | $ (46,030) | $ 9 | 46,021 | ||||
Issuance of common stock upon reverse merger (in shares) | 19,228,595 | ||||||
Issuance of common stock upon reverse merger | $ 19 | 18,902 | 18,921 | ||||
Exercise of stock options (in shares) | 13,460 | ||||||
Exercise of stock options | 22 | 22 | |||||
Share-based compensation | 942 | 942 | |||||
Net loss | (10,310) | (10,310) | |||||
Balance (in shares) at Dec. 31, 2016 | 38,131,303 | ||||||
Balance at Dec. 31, 2016 | $ 38 | 80,686 | (60,142) | 20,582 | |||
Exercise of stock options (in shares) | 87,357 | ||||||
Exercise of stock options | 144 | 144 | |||||
Share-based compensation | 2,707 | 2,707 | |||||
Net loss | (12,308) | (12,308) | |||||
Balance (in shares) at Dec. 31, 2017 | 38,218,660 | ||||||
Balance at Dec. 31, 2017 | $ 38 | 83,537 | (72,450) | $ 11,125 | |||
Exercise of stock options (in shares) | 2,140 | 2,488 | |||||
Exercise of stock options | $ 0 | 4 | $ 4 | ||||
Share-based compensation | 2,774 | 2,774 | |||||
Net loss | (13,987) | (13,987) | |||||
Adjustments to opening balance for change in accounting principle at Dec. 31, 2017 | 76 | 76 | |||||
Sale of common stock and warrants, net of issuance costs of $200 | $ 5 | 3,795 | 3,800 | ||||
Sale of common stock and warrants, net of issuance costs of $200 (in shares) | 5,333,332 | ||||||
Restricted stock units vested and issued (in shares) | 57,108 | ||||||
Balance (in shares) at Dec. 31, 2018 | 43,611,240 | ||||||
Balance at Dec. 31, 2018 | $ 43 | $ 90,110 | $ (86,361) | $ 3,792 |
Consolidated Statements of St_2
Consolidated Statements of Stockholders' Equity (Deficit) (Parentheticals) | 12 Months Ended |
Dec. 31, 2018USD ($) | |
Additional Paid-in Capital [Member] | |
Issuance costs | $ 200,000 |
Issuance costs | $ 200,000 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Operating activities: | |||
Net loss | $ (13,987,000) | $ (12,308,000) | $ (10,310,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Write-off of inventory | 597,000 | ||
Depreciation and amortization | 88,000 | 78,000 | 39,000 |
Change in fair value of convertible preferred stock warrant liability | (250,000) | ||
Change in fair value of maturity date preferred stock warrant liability | (10,000) | ||
Change in fair value of convertible shareholder notes derivative liability | 1,224,000 | ||
Share-based Compensation, Total | 2,774,000 | 2,707,000 | 942,000 |
Non-cash interest expense on convertible shareholder notes | 1,736,000 | ||
Changes in operating assets and liabilities: | |||
Accounts receivable | (179,000) | (21,000) | 33,000 |
Inventory | 49,000 | (56,000) | 27,000 |
Prepaid expenses and other current assets | (104,000) | 16,000 | (110,000) |
Other assets | (11,000) | ||
Accounts payable | 119,000 | 377,000 | (17,000) |
Accrued liabilities excluding accrued interest on convertible note | 240,000 | 415,000 | 530,000 |
Deferred revenue | (65,000) | 96,000 | 32,000 |
Deferred rent | (4,000) | 25,000 | 26,000 |
Net cash used in operating activities | (11,069,000) | (8,671,000) | (5,522,000) |
Investing activities: | |||
Purchase of property and equipment | (66,000) | (136,000) | |
Cash acquired in reverse merger | 19,017,000 | ||
Payment of transaction costs of reverse merger | (96,000) | ||
Purchase of short-term investments | (1,800,000) | ||
Maturity of short-term investments | 1,800,000 | ||
Net cash (used) provided by investing activities | (66,000) | (136,000) | 18,921,000 |
Financing activities: | |||
Proceeds from sales of common stock and warrants, net of issuance costs of $200 | 3,800,000 | ||
Proceeds from issuance of convertible notes and warrants | 4,374,000 | ||
Proceeds from the exercise of common stock options | 4,000 | 144,000 | 22,000 |
Net cash provided by financing activities | 3,804,000 | 144,000 | 4,396,000 |
Net (decrease) increase in cash and cash equivalents | (7,331,000) | (8,663,000) | 17,795,000 |
Cash and cash equivalents at beginning of period | 12,689,000 | 21,352,000 | 3,557,000 |
Cash and cash equivalents at end of period | 5,358,000 | 12,689,000 | 21,352,000 |
Supplemental disclosure for noncash investing and financing activities: | |||
Exchange of convertible preferred stock warrants for common stock | 25,000 | ||
Conversion of convertible shareholder notes and related interest payable | 12,156,000 | ||
Reclassification of convertible shareholder notes derivative liability | 2,268,000 | ||
Conversion of preferred stock | $ 46,030,000 |
Consolidated Statements of Ca_2
Consolidated Statements of Cash Flows (Parentheticals) - USD ($) | Dec. 24, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Issuance costs | $ 200,000 | $ 200,000 |
Note 1 - Summary of Business
Note 1 - Summary of Business | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Business Description and Basis of Presentation [Text Block] | ( 1 ) Summary of Business (a) Description of Business BioCardia, Inc., or the Company, is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. Its lead therapeutic candidate is the CardiAMP cell therapy system and its second The Company has three 1 2 3 |
Note 2 - Significant Accounting
Note 2 - Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | ( 2 ) Significant Accounting Policies (a) Basis of Presentation and Consolidation These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All material intercompany accounts and transactions have been eliminated during the consolidation process. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. (b) Liquidity - Going Concern The Company has incurred net losses and negative cash flows from operations since its inception and had an accumulated deficit of $86.4 December 31, 2018. $5.4 December 31, 2018 not second 2019. one not The Company’s ability to continue as a going concern and to continue further development of its therapeutic candidates through and beyond the second 2019, not not may may (c) Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires Company management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property and equipment; allowances for doubtful accounts and sales returns; inventory valuation; and share-based compensation. (d) Cash Equivalents The Company classifies all highly liquid investments with an original maturity date of 90 (e) Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At December 31, 2018, one not not (f) Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and do not not $9,000 $6,000 December 31, 2018 2017, (g) Inventory Inventory is stated at the lower of cost or net realizable value. Cost is determined using the average-cost method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company analyzes its inventory levels quarterly and writes down inventory that has become obsolete or has a cost basis in excess of its expected net realizable value or inventory quantities in excess of expected requirements. Excess requirements are determined based on comparison of existing inventories to forecasted sales, with consideration given to inventory shelf life. Expired inventory is disposed of and the related costs are recognized in cost of goods sold. ( h ) Property and Equipment, Net Property and equipment, net, are carried at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets, as described in the table below. Maintenance and repairs are expensed as incurred. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is reflected in the accompanying consolidated statements of operations. Asset Estimated useful lives (in years) Computer equipment and software 3 Laboratory and manufacturing equipment 3 Furniture and fixtures 3 Leasehold improvements 5 years or lease term, if shorter ( i ) Long-Lived Assets The carrying value of long-lived assets, including property and equipment, is reviewed for impairment whenever events or changes in circumstances indicate that the asset may not December 31, 2018, no ( j ) Clinical Trial Accruals As part of the process of preparing its consolidated financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiation and may not not may may ( k ) Derivatives The Company accounts for its derivative instruments as either assets or liabilities on the consolidated balance sheet and measures them at fair value. Derivatives are adjusted to fair value through other (expense) income, net in the consolidated statements of operations. ( l ) Deferred Rent The Company’s lease for its facility provides for fixed increases in minimum annual rental payments. The total amount of rental payments due over the lease term is charged to rent expense ratably over the life of the lease. Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis. ( m ) Revenue Recognition Net product revenue Collaboration agreement revenue In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may Amounts received from customers in advance of revenue recognition are recorded as deferred revenue on the consolidated balance sheets. ( n ) Shipping Costs Costs incurred for the shipping of products to customers totaled approximately $6,000, $5,000 $7,000 December 31, 2018, 2017 2016, ( o ) Product Warranties The Company provides a standard warranty of serviceability on all its products for the duration of the product’s shelf life, which is two not December 31, 2018 2017. ( p ) Research and Development The Company’s research and development costs are expensed as incurred. Research and development expense include the costs of basic research activities as well as other research, engineering, and technical effort required to develop new products or services or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses and support costs for collaborative partnering programs wherein the Company provides biotherapeutic delivery systems and customer training and support for their use in clinical trials and studies. The Company’s research and development costs consist primarily of: • Salaries, benefits and other personnel-related expenses, including share-based compensation • Fees paid for services provided by clinical research organizations, research institutions, consultants and other outside service providers • Costs to acquire and manufacture materials used in research and development activities and clinical trials • Laboratory consumables and supplies • Facility-related expenses allocated to research and development activities • Fees to collaborators to license technology • Depreciation expense for equipment used for research and development and clinical purposes. ( q ) Share-Based Compensation The Company measures and recognizes share-based compensation expense for equity awards to employees, directors and consultants based on fair value at the grant date. The Company uses the Black-Scholes option pricing model to calculate fair value. Share-based compensation expense recognized in the consolidated statements of operations is based on the period the services are performed. The Company accounts for forfeitures as they occur. The compensation cost for restricted stock awards is based on the closing price of the Company’s common stock on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period. For options granted to nonemployees, the Company revalues the unearned portion of the share-based compensation and the resulting change in fair value is recognized in the consolidated statements of operations over the period the related services are rendered. The Black-Scholes option pricing model (BSM) requires the input of subjective assumptions, including the risk-free interest rate, the expected volatility in the value of the Company’s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management’s judgment. If factors change and different assumptions are used, our share-based compensation expense could be materially different in the future. These assumptions are estimated as follows: Risk-free Interest Rate The risk-free interest rate assumption is based on the zero Expected Volatility The Company has limited historical data of its own to utilize in determining expected volatility. As such we based our volatility assumption on a combined weighted average of our own historical data and that of a selected peer group. The peer group was developed based on companies in the biotechnology and medical device industries whose shares are publicly-traded. Expected Term The expected term represents the period of time that options are expected to be outstanding. As the Company does not ( r ) Income Taxes The Company accounts for income taxes based on the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets, liabilities, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not not In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, forecasts of future taxable income, and ongoing tax planning. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not The Company recognizes and measures benefits for uncertain tax positions using a two first not not second 50% No ( s ) Fair Value of Financial Instruments The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the consolidated financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Where observable prices or inputs are not The Company’s financial assets and liabilities consist principally of cash and cash equivalents, accounts receivable, and accounts payable. The fair value of the Company’s cash equivalents is determined based on quoted prices in active markets for identical assets. The recorded values of the Company’s accounts receivable and accounts payable approximate their current fair values due to the relatively short-term nature of these accounts. ( t ) Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Common stock equivalents are comprised of restricted stock units, warrants to purchase common stock and options outstanding under our stock option plans. For all periods presented, there is no ( u ) Recently Adopted Accounting Pronouncements In May 2014, No. 2014 09, 605, 606, 2015 2016, 606 January 1, 2018 In May 2017, No. 2017 09 718 2017 09 718. 2016 01 January 1, 2018, not ( v ) Recent Accounting Pronouncements In February 2016, No. 2016 02—Leases, 842 2016 02 July 2018, No. 2018 11, 842 No. 2018 11. No. 2018 11, 2016 02, 12 January 1, 2019 $1.5 $1.6 In June 2018, No. 2018 07, Stock Compensation (Topic 718 2018 07 2018 07 718, 2018 07 505 50, 2018 07 December 15, 2018, In August 2018, No. 2018 13, Fair Value Measurement (Topic 820 2018 13 820. 3 2018 13 December 15, 2019, In November 2018, No. 2018 18, Collaborative Arrangements (Topic 808 808 606 2018 18” 2018 18 606 606 2018 18 December 15, 2019, 2018 18 606. 2018 18 Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did not not |
Note 3 - Reverse Merger
Note 3 - Reverse Merger | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Assets Acquired Through Merger [Text Block] | ( 3 ) Reverse Merger On October 24, 2016, 1. not $19 No $96,000 The Merger is considered a tax free reverse triangular merger for tax purposes pursuant to Internal Revenue Code Sections 368 368 2 none 382 |
Note 4 - Fair Value Measurement
Note 4 - Fair Value Measurements | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | ( 4 ) Fair Value Measurements The fair value of financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The Company follows a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into the following three Level 1 Level 2 not Level 3 no The following table sets forth the fair value of our financial assets measured on a recurring basis as of December 31, 2018 2017 As of December 31, 2018 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 5,358 $ — $ — $ 5,358 As of December 31, 2017 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 12,689 $ — $ — $ 12,689 |
Note 5 - Inventories
Note 5 - Inventories | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | ( 5 ) Inventories Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories consist of the following (in thousands): December 31, 2018 2017 Raw materials $ 79 $ 70 Work in process 39 92 Finished goods 23 29 Total $ 141 $ 191 Write downs for excess or expired inventory are based on management’s estimates of forecasted usage of inventories and are included in cost of goods sold. A significant change in the timing or level of demand for certain products as compared to forecasted amounts may $12,000, $33,000 $52,000 December 31, 2018, 2017 2016, |
Note 6 - Property and Equipment
Note 6 - Property and Equipment, Net | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | ( 6 ) Property and Equipment, Net Property and equipment, net consist of the following (in thousands): December 31, 2018 2017 Computer equipment and software $ 119 106 Laboratory and manufacturing equipment 481 447 Furniture and fixtures 55 48 Leasehold improvements 332 326 Construction in progress 3 — Property and equipment, gross 990 927 Less accumulated depreciation (845 ) (758 ) Property and equipment, net $ 145 169 Depreciation expense totaled approximately $88,000, $78,000 $39,000 December 31, 2018, 2017 2016, |
Note 7 - Commitments
Note 7 - Commitments | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Commitments Disclosure [Text Block] | ( 7 ) Commitments In November 2016, 60 January 1, 2017 December 31, 2021. $601,000 December 31, 2018 2017, $321,000 December 31, 2016. December 31, 2018 Years ending December 31: 2019 $ 612 2020 630 2021 649 Total $ 1,891 |
Note 8 - Collaborative Agreemen
Note 8 - Collaborative Agreements | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Collaborative Arrangement Disclosure [Text Block] | ( 8 ) Collaborative Agreements The Company has entered into various collaborations related to clinical development. These agreements allow partners to utilize the Company’s enabling biotherapeutic delivery systems, including training and support during clinical and pre-clinical delivery of biotherapeutics. Under the terms of these agreements, the Company typically receives a use fee and payments for the systems and services provided. The Company gains access to certain data generated by its partners for use in its own product development efforts and also receives nonexclusive patent rights to any BioCardia technology improvement inventions. |
Note 9 - Accrued Expenses and O
Note 9 - Accrued Expenses and Other Current Liabilities | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Accrued Liabilities and Other Current Liabilities Disclosure [Text Block] | ( 9 ) Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): December 31, 2018 2017 Accrued expenses $ 495 $ 465 Accrued clinical trial costs 276 74 Grant liability 645 663 Customer deposits 112 61 Total $ 1,528 $ 1,263 |
Note 10 - Sales of Unregistered
Note 10 - Sales of Unregistered Securities | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Restricted Stock Shares Activity [Text Block] | ( 10 Sales of Unregistered Securities On December 24, 2018, 5,333,332 $0.75 one 2,666,666 $0.75 $3.8 $200,000 December 24, 2023. six no not December 24, 2018. |
Note 11 - Share-based Compensat
Note 11 - Share-based Compensation | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | ( 11 ) Share-Based Compensation BioCardia Lifesciences adopted, and the BioCardia Lifesciences shareholders approved, the 2002 2002 “2002 2002 not not 2002 2016, 2016 “2016 2016 2016 2002 2016 four ten no December 31, 2018, 7,932,494 2016 The Company recognizes in the consolidated statements of operations the grant-date fair value of stock options and other equity-based compensation. Share-based compensation expense for the years ended December 31, 2018, 2017 2016 Years ended December 31, 2018 2017 2015 Cost of goods sold $ 143 $ 140 $ 14 Research and development 953 678 127 Selling, general and administrative 1,678 1,889 801 Share-based compensation expense $ 2,774 $ 2,707 $ 942 The following table summarizes activity under the Company’s stock option plans, including the 2002 2016 Options outstanding Number of shares Weighted average exercise price Weighted average remaining contractual term (years) Aggregate intrisinsic value Balance, December 31, 2017 4,213,100 $ 2.96 8.1 $ 1,890 Stock options granted 1,698,452 2.41 Stock options exercised (2,488 ) 1.80 Stock options canceled (431,700 ) 2.92 Balance, December 31, 2018 5,477,364 $ 2.80 7.8 $ - Exercisable and vested, December 31, 2018 2,346,990 $ 2.72 6.9 $ - The total intrinsic value of options exercised during the years ended December 31, 2018, 2017 2016 $3,000, $400,000 $144,000, December 31, 2018, 2017 2016 $1.72, $5.80 $1.33 Employee Share-Based Compensation During the years ended December 31, 2018 2017, 1,698,452 796,399 Years ended December 31, 2018 2017 2016 Risk-free interest rate 2.66 - 2.89% 1.76 - 2.25% 1.28 - 1.58% Volatility 81 - 83% 81 - 89% 88% Dividend yield None None None Expected term (in years) 6.25 5.00 - 6.25 6.25 Unrecognized share-based compensation for non-employee directors and employee options granted through December 31, 2018 $5.0 2.4 Non-Employee Director Share-Based Compensation (RSUs) During the year ended December 31, 2018, 226,471 The following summarizes the activity of non-vested RSUs: Weighted average grant date Number of fair value shares per share Balance, December 31, 2017 97,996 $ 8.71 RSUs granted 226,471 $ 1.36 RSUs vested (57,108 ) $ 7.03 RSUs forfeited - — Balance, December 31, 2018 267,359 $ 2.84 Unrecognized share-based compensation for employee RSUs granted through December 31, 2018 $235,000 1.0 Nonemployee Share-Based Compensation During the year ended December 31, 2018, 2017 2016, zero 46,254 490,849 $176,000, $768,000 $545,000 December 31, 2018, 2017 2016 December 31, 2018 $204,000 1.8 The Company accounts for share-based compensation arrangements with nonemployees, using the Black Scholes option pricing model, based on the fair value as these instruments vest. Accordingly, at each reporting date, the Company revalues the unearned portion of the share-based compensation and the resulting change in fair value is recognized in the consolidated statements of operations over the period the related services are rendered. The following assumptions were used to value the awards. Years ended December 31, 2018 2017 2016 Risk-free interest rate 2.80 - 2.95% 2.25 - 2.40% 1.60 - 2.42% Volatility 78 - 85% 81 - 87% 89 - 91% Dividend yield None None None Expected term (in years) 7.6 - 8.8 8.6 - 9.8 9.6 - 9.9 |
Note 12 - Concentrations
Note 12 - Concentrations | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Concentration Risk Disclosure [Text Block] | ( 12 ) Concentrations Most of the Company’s customers are located in the United States. One customer accounted for approximately 29% 2018 no 10% 2017 2016. 23% December 31, 2018, 20% December 31, 2017 29% December 31, 2016. |
Note 13 - Net Loss Per Share
Note 13 - Net Loss Per Share | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | ( 13 ) Net Loss per Share The following table sets forth the computation of the basic and diluted net loss per share for the years ended December 31, 2018, 2017 2016 Years ended December 31, 2018 2017 2016 Numerator: Net loss $ (13,987 ) $ (12,308 ) $ (10,310 ) Denominator: Weighted average shares used to compute net loss per share, basic and diluted 38,377,606 38,160,543 8,368,284 Net loss per share, basic and diluted $ (0.36 ) $ (0.32 ) $ (1.23 ) The following weighted-average outstanding common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: December 31, 2018 2017 2016 Stock options to purchase common stock 5,477,364 4,213,100 3,491,937 Unvested restricted stock units 267,359 97,996 - Common stock warrants 2,666,666 - - Total 8,411,389 4,311,096 3,491,937 |
Note 14 - Income Taxes
Note 14 - Income Taxes | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | ( 14 ) Income Taxes The Company’s provision for income taxes for the years ended December 31, 2018, 2017 2016 $0 The provision for income taxes differs from the amount which would result by applying the federal statutory income tax rate to pre-tax loss for the years ended December 31, 2018, 2017 2016. Years ended December 31, 2018 2017 2016 Tax at federal statutory rate $ (2,937 ) $ (4,185 ) $ (3,505 ) State, net of federal benefit (455 ) (1,238 ) (315 ) Research and development credit (236 ) (135 ) (89 ) Stock-based compensation 440 344 136 Nondeductible interest — — 590 Warrant and derivative revaluation — — 328 Change in Federal tax rate — 8,172 — Other 22 7 94 Change in valuation allowance 3,166 (2,965 ) 2,761 Total provision for income taxes $ — $ — $ — Deferred income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss and tax credit carryforwards, net of any adjustment for unrecognized tax benefits. The components of the net deferred income tax assets as of December 31, 2018 2017 December 31, 2018 2017 Accrued compensation $ 84 $ 110 Inventory adjustments 276 449 Depreciation and amortization - noncurrent 113 146 Share-based compensation 648 558 Net operating loss and tax credit carryforwards - noncurrent 20,698 17,368 Other 12 34 Gross deferred tax asset 21,831 18,665 Valuation allowance (21,831 ) (18,665 ) Net deferred tax asset $ — $ — The Company has approximately $69.2 $54.4 December 31, 2018. 2022 2028 2018 no may may may one not 50% three Generally, utilization of the net operating loss carryforwards and credits may 382, 383, 1986, may not 382 At December 31, 2018, $2.0 $1.5 2028. no The Company does not not not December 31, 2018 2017. December 31, 2018 $3.2 December 31, 2017 $3.0 No The aggregate changes in the balance of gross unrecognized tax benefits were as follows (in thousands): December 31, 2018 2017 Balance, beginning of year $ 725 $ 608 Additions based on tax positions related to the current year 166 117 Additions (reductions) for tax positions related to prior years — — Balance, end of year $ 891 $ 725 Recognition of approximately $636,000 $511,000 December 31, 2018 2017 2017 2018 The Company is subject to U.S. federal, California, Colorado, Florida and Minnesota income taxes. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The Company was incorporated in 2002 US Tax Reform - Impact of the Tax Cuts and Jobs Act On December 22, 2017, 1 35% 21%, one After the enactment of the Tax Act, the Securities and Exchange Commission ("SEC") staff issued Staff Accounting Bulletin No. 118 118" not December 31, 2017, 34% 21% December 31, 2018, no The Company has considered required policy elections with respect to its treatment of potential base erosion anti-abuse tax (“BEAT”) and Global Intangible Low Taxed Income (“GILTI”). Companies can either account for taxes on BEAT and GILTI as incurred or recognize deferred taxes when basis differences exist that are expected to affect the amount of the BEAT and GILTI inclusion upon reversal. The Company has considered the provisions of the Act associated with BEAT and GILTI and noted that these are not December 31, 2018. |
Note 15 - Contingencies
Note 15 - Contingencies | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Contingencies Disclosure [Text Block] | ( 15 ) Contingencies The Company may not |
Note 16 - Grant Funding
Note 16 - Grant Funding | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Grant Funding [Text Block] | ( 16 ) Grant Funding In June 2016, 1998 not $750,000 three As of December 31, 2018, $750,000 $105,000 December 31, 2018. $645,000 December 31, 2018. |
Note 17 - Related Party Transac
Note 17 - Related Party Transactions | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | ( 17 ) Related Party Transactions In August 2016, 418,977 4 $1.80 $142,000 $480,000 December 31, 2018 2017, $5.3 4 one 5% |
Note 18 - Employee Benefit Plan
Note 18 - Employee Benefit Plans | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Pension and Other Postretirement Benefits Disclosure [Text Block] | ( 18 ) Employee Benefit Plans The Company’s U.S. employees are eligible to participate in a retirement and savings plan that qualifies under Section 401 may 75% not not December 31, 2017 2016, $26,000 December 31, 2018. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2018 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | (a) Basis of Presentation and Consolidation These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All material intercompany accounts and transactions have been eliminated during the consolidation process. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. |
Going Concern and Liquidity [Policy Text Block] | (b) Liquidity - Going Concern The Company has incurred net losses and negative cash flows from operations since its inception and had an accumulated deficit of $86.4 December 31, 2018. $5.4 December 31, 2018 not second 2019. one not The Company’s ability to continue as a going concern and to continue further development of its therapeutic candidates through and beyond the second 2019, not not may may |
Use of Estimates, Policy [Policy Text Block] | (c) Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires Company management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property and equipment; allowances for doubtful accounts and sales returns; inventory valuation; and share-based compensation. |
Cash and Cash Equivalents, Policy [Policy Text Block] | (d) Cash Equivalents The Company classifies all highly liquid investments with an original maturity date of 90 |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | (e) Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At December 31, 2018, one not not |
Trade and Other Accounts Receivable, Policy [Policy Text Block] | (f) Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and do not not $9,000 $6,000 December 31, 2018 2017, |
Inventory, Policy [Policy Text Block] | (g) Inventory Inventory is stated at the lower of cost or net realizable value. Cost is determined using the average-cost method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company analyzes its inventory levels quarterly and writes down inventory that has become obsolete or has a cost basis in excess of its expected net realizable value or inventory quantities in excess of expected requirements. Excess requirements are determined based on comparison of existing inventories to forecasted sales, with consideration given to inventory shelf life. Expired inventory is disposed of and the related costs are recognized in cost of goods sold. |
Property, Plant and Equipment, Policy [Policy Text Block] | ( h ) Property and Equipment, Net Property and equipment, net, are carried at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets, as described in the table below. Maintenance and repairs are expensed as incurred. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is reflected in the accompanying consolidated statements of operations. Asset Estimated useful lives (in years) Computer equipment and software 3 Laboratory and manufacturing equipment 3 Furniture and fixtures 3 Leasehold improvements 5 years or lease term, if shorter |
Property, Plant and Equipment, Impairment [Policy Text Block] | ( i ) Long-Lived Assets The carrying value of long-lived assets, including property and equipment, is reviewed for impairment whenever events or changes in circumstances indicate that the asset may not December 31, 2018, no |
Clinical Trial Accruals, Policy [Policy Text Block] | ( j ) Clinical Trial Accruals As part of the process of preparing its consolidated financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiation and may not not may may |
Derivatives, Policy [Policy Text Block] | ( k ) Derivatives The Company accounts for its derivative instruments as either assets or liabilities on the consolidated balance sheet and measures them at fair value. Derivatives are adjusted to fair value through other (expense) income, net in the consolidated statements of operations. |
Lessee, Leases [Policy Text Block] | ( l ) Deferred Rent The Company’s lease for its facility provides for fixed increases in minimum annual rental payments. The total amount of rental payments due over the lease term is charged to rent expense ratably over the life of the lease. Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis. |
Revenue Recognition, Policy [Policy Text Block] | ( m ) Revenue Recognition Net product revenue Collaboration agreement revenue In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may Amounts received from customers in advance of revenue recognition are recorded as deferred revenue on the consolidated balance sheets. |
Shipping and Handling, Policy [Policy Text Block] | ( n ) Shipping Costs Costs incurred for the shipping of products to customers totaled approximately $6,000, $5,000 $7,000 December 31, 2018, 2017 2016, |
Standard Product Warranty, Policy [Policy Text Block] | ( o ) Product Warranties The Company provides a standard warranty of serviceability on all its products for the duration of the product’s shelf life, which is two not December 31, 2018 2017. |
Research and Development Expense, Policy [Policy Text Block] | ( p ) Research and Development The Company’s research and development costs are expensed as incurred. Research and development expense include the costs of basic research activities as well as other research, engineering, and technical effort required to develop new products or services or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses and support costs for collaborative partnering programs wherein the Company provides biotherapeutic delivery systems and customer training and support for their use in clinical trials and studies. The Company’s research and development costs consist primarily of: • Salaries, benefits and other personnel-related expenses, including share-based compensation • Fees paid for services provided by clinical research organizations, research institutions, consultants and other outside service providers • Costs to acquire and manufacture materials used in research and development activities and clinical trials • Laboratory consumables and supplies • Facility-related expenses allocated to research and development activities • Fees to collaborators to license technology • Depreciation expense for equipment used for research and development and clinical purposes. |
Compensation Related Costs, Policy [Policy Text Block] | ( q ) Share-Based Compensation The Company measures and recognizes share-based compensation expense for equity awards to employees, directors and consultants based on fair value at the grant date. The Company uses the Black-Scholes option pricing model to calculate fair value. Share-based compensation expense recognized in the consolidated statements of operations is based on the period the services are performed. The Company accounts for forfeitures as they occur. The compensation cost for restricted stock awards is based on the closing price of the Company’s common stock on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period. For options granted to nonemployees, the Company revalues the unearned portion of the share-based compensation and the resulting change in fair value is recognized in the consolidated statements of operations over the period the related services are rendered. The Black-Scholes option pricing model (BSM) requires the input of subjective assumptions, including the risk-free interest rate, the expected volatility in the value of the Company’s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management’s judgment. If factors change and different assumptions are used, our share-based compensation expense could be materially different in the future. These assumptions are estimated as follows: Risk-free Interest Rate The risk-free interest rate assumption is based on the zero Expected Volatility The Company has limited historical data of its own to utilize in determining expected volatility. As such we based our volatility assumption on a combined weighted average of our own historical data and that of a selected peer group. The peer group was developed based on companies in the biotechnology and medical device industries whose shares are publicly-traded. Expected Term The expected term represents the period of time that options are expected to be outstanding. As the Company does not |
Income Tax, Policy [Policy Text Block] | ( r ) Income Taxes The Company accounts for income taxes based on the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets, liabilities, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not not In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, forecasts of future taxable income, and ongoing tax planning. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not The Company recognizes and measures benefits for uncertain tax positions using a two first not not second 50% No |
Fair Value of Financial Instruments, Policy [Policy Text Block] | ( s ) Fair Value of Financial Instruments The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the consolidated financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Where observable prices or inputs are not The Company’s financial assets and liabilities consist principally of cash and cash equivalents, accounts receivable, and accounts payable. The fair value of the Company’s cash equivalents is determined based on quoted prices in active markets for identical assets. The recorded values of the Company’s accounts receivable and accounts payable approximate their current fair values due to the relatively short-term nature of these accounts. |
Earnings Per Share, Policy [Policy Text Block] | ( t ) Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Common stock equivalents are comprised of restricted stock units, warrants to purchase common stock and options outstanding under our stock option plans. For all periods presented, there is no |
New Accounting Pronouncements, Policy [Policy Text Block] | ( u ) Recently Adopted Accounting Pronouncements In May 2014, No. 2014 09, 605, 606, 2015 2016, 606 January 1, 2018 In May 2017, No. 2017 09 718 2017 09 718. 2016 01 January 1, 2018, not ( v ) Recent Accounting Pronouncements In February 2016, No. 2016 02—Leases, 842 2016 02 July 2018, No. 2018 11, 842 No. 2018 11. No. 2018 11, 2016 02, 12 January 1, 2019 $1.5 $1.6 In June 2018, No. 2018 07, Stock Compensation (Topic 718 2018 07 2018 07 718, 2018 07 505 50, 2018 07 December 15, 2018, In August 2018, No. 2018 13, Fair Value Measurement (Topic 820 2018 13 820. 3 2018 13 December 15, 2019, In November 2018, No. 2018 18, Collaborative Arrangements (Topic 808 808 606 2018 18” 2018 18 606 606 2018 18 December 15, 2019, 2018 18 606. 2018 18 Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did not not |
Note 2 - Significant Accounti_2
Note 2 - Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Property, Plant and Equipment, Useful Life [Table Text Block] | Asset Estimated useful lives (in years) Computer equipment and software 3 Laboratory and manufacturing equipment 3 Furniture and fixtures 3 Leasehold improvements 5 years or lease term, if shorter |
Note 4 - Fair Value Measureme_2
Note 4 - Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | As of December 31, 2018 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 5,358 $ — $ — $ 5,358 As of December 31, 2017 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 12,689 $ — $ — $ 12,689 |
Note 5 - Inventories (Tables)
Note 5 - Inventories (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | December 31, 2018 2017 Raw materials $ 79 $ 70 Work in process 39 92 Finished goods 23 29 Total $ 141 $ 191 |
Note 6 - Property and Equipme_2
Note 6 - Property and Equipment, Net (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | December 31, 2018 2017 Computer equipment and software $ 119 106 Laboratory and manufacturing equipment 481 447 Furniture and fixtures 55 48 Leasehold improvements 332 326 Construction in progress 3 — Property and equipment, gross 990 927 Less accumulated depreciation (845 ) (758 ) Property and equipment, net $ 145 169 |
Note 7 - Commitments (Tables)
Note 7 - Commitments (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Lessee, Operating Lease, Disclosure [Table Text Block] | Years ending December 31: 2019 $ 612 2020 630 2021 649 Total $ 1,891 |
Note 9 - Accrued Expenses and_2
Note 9 - Accrued Expenses and Other Current Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block] | <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Accrued expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">495</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">465</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Accrued clinical trial costs</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">276</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">74</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Grant liability</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">645</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">663</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Customer deposits</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">112</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">61</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,528</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,263</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>" id="sjs-B4"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Accrued expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">495</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">465</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Accrued clinical trial costs</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">276</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">74</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Grant liability</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">645</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">663</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Customer deposits</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">112</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">61</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,528</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,263</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div> |
Note 11 - Share-based Compens_2
Note 11 - Share-based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Share-based Compensation, Expense [Table Text Block] | Years ended December 31, 2018 2017 2015 Cost of goods sold $ 143 $ 140 $ 14 Research and development 953 678 127 Selling, general and administrative 1,678 1,889 801 Share-based compensation expense $ 2,774 $ 2,707 $ 942 |
Share-based Compensation, Stock Options, Activity [Table Text Block] | Options outstanding Number of shares Weighted average exercise price Weighted average remaining contractual term (years) Aggregate intrisinsic value Balance, December 31, 2017 4,213,100 $ 2.96 8.1 $ 1,890 Stock options granted 1,698,452 2.41 Stock options exercised (2,488 ) 1.80 Stock options canceled (431,700 ) 2.92 Balance, December 31, 2018 5,477,364 $ 2.80 7.8 $ - Exercisable and vested, December 31, 2018 2,346,990 $ 2.72 6.9 $ - |
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] | Weighted average grant date Number of fair value shares per share Balance, December 31, 2017 97,996 $ 8.71 RSUs granted 226,471 $ 1.36 RSUs vested (57,108 ) $ 7.03 RSUs forfeited - — Balance, December 31, 2018 267,359 $ 2.84 |
Non-employee Stock Options [Member] | |
Notes Tables | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Years ended December 31, 2018 2017 2016 Risk-free interest rate 2.80 - 2.95% 2.25 - 2.40% 1.60 - 2.42% Volatility 78 - 85% 81 - 87% 89 - 91% Dividend yield None None None Expected term (in years) 7.6 - 8.8 8.6 - 9.8 9.6 - 9.9 |
Employee Stock Option [Member] | |
Notes Tables | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Years ended December 31, 2018 2017 2016 Risk-free interest rate 2.66 - 2.89% 1.76 - 2.25% 1.28 - 1.58% Volatility 81 - 83% 81 - 89% 88% Dividend yield None None None Expected term (in years) 6.25 5.00 - 6.25 6.25 |
Note 13 - Net Loss Per Share (T
Note 13 - Net Loss Per Share (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Years ended December 31, 2018 2017 2016 Numerator: Net loss $ (13,987 ) $ (12,308 ) $ (10,310 ) Denominator: Weighted average shares used to compute net loss per share, basic and diluted 38,377,606 38,160,543 8,368,284 Net loss per share, basic and diluted $ (0.36 ) $ (0.32 ) $ (1.23 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | December 31, 2018 2017 2016 Stock options to purchase common stock 5,477,364 4,213,100 3,491,937 Unvested restricted stock units 267,359 97,996 - Common stock warrants 2,666,666 - - Total 8,411,389 4,311,096 3,491,937 |
Note 14 - Income Taxes (Tables)
Note 14 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | Years ended December 31, 2018 2017 2016 Tax at federal statutory rate $ (2,937 ) $ (4,185 ) $ (3,505 ) State, net of federal benefit (455 ) (1,238 ) (315 ) Research and development credit (236 ) (135 ) (89 ) Stock-based compensation 440 344 136 Nondeductible interest — — 590 Warrant and derivative revaluation — — 328 Change in Federal tax rate — 8,172 — Other 22 7 94 Change in valuation allowance 3,166 (2,965 ) 2,761 Total provision for income taxes $ — $ — $ — |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | December 31, 2018 2017 Accrued compensation $ 84 $ 110 Inventory adjustments 276 449 Depreciation and amortization - noncurrent 113 146 Share-based compensation 648 558 Net operating loss and tax credit carryforwards - noncurrent 20,698 17,368 Other 12 34 Gross deferred tax asset 21,831 18,665 Valuation allowance (21,831 ) (18,665 ) Net deferred tax asset $ — $ — |
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] | December 31, 2018 2017 Balance, beginning of year $ 725 $ 608 Additions based on tax positions related to the current year 166 117 Additions (reductions) for tax positions related to prior years — — Balance, end of year $ 891 $ 725 |
Note 2 - Significant Accounti_3
Note 2 - Significant Accounting Policies (Details Textual) - USD ($) | 12 Months Ended | ||||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Jan. 01, 2019 | Dec. 31, 2015 | |
Retained Earnings (Accumulated Deficit), Ending Balance | $ (86,361,000) | $ (72,450,000) | |||
Cash and Cash Equivalents, at Carrying Value, Ending Balance | 5,358,000 | 12,689,000 | $ 21,352,000 | $ 3,557,000 | |
Allowance for Doubtful Accounts Receivable, Current, Ending Balance | 9,000 | 6,000 | |||
Impairment of Long-Lived Assets Held-for-use | 0 | ||||
Cost of Goods and Services Sold, Total | $ 517,000 | 690,000 | 746,000 | ||
Standard Product Warranty, Term | 2 years | ||||
Standard Product Warranty Accrual, Ending Balance | $ 0 | 0 | |||
Income Tax Examination, Penalties and Interest Accrued, Total | 0 | ||||
Accounting Standards Update 2018-11 [Member] | |||||
Operating Lease, Right-of-Use Asset | $ 1,500,000 | ||||
Operating Lease, Liability, Total | $ 1,600,000 | ||||
Shipping and Handling [Member] | |||||
Cost of Goods and Services Sold, Total | $ 6,000 | $ 5,000 | $ 7,000 |
Note 2 - Significant Accounti_4
Note 2 - Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details) | 12 Months Ended |
Dec. 31, 2018 | |
Computer Equipment and Software [Member] | |
Estimated useful lives (Year) | 3 years |
Laboratory and Manufacturing Equipment [Member] | |
Estimated useful lives (Year) | 3 years |
Furniture and Fixtures [Member] | |
Estimated useful lives (Year) | 3 years |
Leasehold Improvements [Member] | |
Estimated useful lives | 5 years or lease term, if shorter |
Note 3 - Reverse Merger (Detail
Note 3 - Reverse Merger (Details Textual) - USD ($) | Oct. 24, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Cash Acquired in Reverse Merger | $ 19,017,000 | |||
Payments of Transaction Costs for Reverse Merger | $ 96,000 | |||
Assets Acquired from Tiger X [Member] | ||||
Cash Acquired in Reverse Merger | $ 19,000,000 | |||
Payments of Transaction Costs for Reverse Merger | $ 96,000 |
Note 4 - Fair Value Measureme_3
Note 4 - Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Assets: | ||
Money market funds | $ 5,358 | $ 12,689 |
Fair Value, Inputs, Level 1 [Member] | ||
Assets: | ||
Money market funds | 5,358 | 12,689 |
Fair Value, Inputs, Level 2 [Member] | ||
Assets: | ||
Money market funds | ||
Fair Value, Inputs, Level 3 [Member] | ||
Assets: | ||
Money market funds |
Note 5 - Inventories (Details T
Note 5 - Inventories (Details Textual) - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Inventory Write-down | $ 597,000 | ||
Cost of Goods Sold [Member] | |||
Inventory Write-down | $ 12,000 | $ 33,000 | $ 52,000 |
Note 5 - Inventories - Summary
Note 5 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Raw materials | $ 79 | $ 70 |
Work in process | 39 | 92 |
Finished goods | 23 | 29 |
Total | $ 141 | $ 191 |
Note 6 - Property and Equipme_3
Note 6 - Property and Equipment, Net (Details Textual) - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Depreciation, Total | $ 88,000 | $ 78,000 | $ 39,000 |
Note 6 - Property and Equipme_4
Note 6 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Property and equipment, gross | $ 990 | $ 927 |
Less accumulated depreciation | (845) | (758) |
Property and equipment, net | 145 | 169 |
Computer Equipment and Software [Member] | ||
Property and equipment, gross | 119 | 106 |
Laboratory and Manufacturing Equipment [Member] | ||
Property and equipment, gross | 481 | 447 |
Furniture and Fixtures [Member] | ||
Property and equipment, gross | 55 | 48 |
Leasehold Improvements [Member] | ||
Property and equipment, gross | 332 | 326 |
Construction in Progress [Member] | ||
Property and equipment, gross | $ 3 |
Note 7 - Commitments (Details T
Note 7 - Commitments (Details Textual) - USD ($) | 12 Months Ended | |||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Nov. 30, 2016 | |
Lessee, Operating Lease, Term of Contract | 5 years | |||
Operating Leases, Rent Expense, Net, Total | $ 601,000 | $ 601,000 | $ 321,000 |
Note 7 - Commitments - Future M
Note 7 - Commitments - Future Minimum Lease Payments (Details) $ in Thousands | Dec. 31, 2018USD ($) |
2019 | $ 612 |
2020 | 630 |
2021 | 649 |
Total | $ 1,891 |
Note 9 - Accrued Expenses and_3
Note 9 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Accrued expenses | $ 495 | $ 465 |
Accrued clinical trial costs | 276 | 74 |
Grant liability | 645 | 663 |
Customer deposits | 112 | 61 |
Total | $ 1,528 | $ 1,263 |
Note 10 - Sales of Unregister_2
Note 10 - Sales of Unregistered Securities (Details Textual) - USD ($) | Dec. 24, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Common Stock, Shares, Issued, Total | 5,333,332 | 43,611,240 | 38,218,660 | |
Sale of Stock, Price Per Share | $ 0.75 | |||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 0.5 | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 2,666,666 | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.75 | |||
Proceeds from Issuance of Common Stock and Warrants | $ 3,800,000 | $ 3,800,000 | ||
Payments of Stock Issuance Costs | $ 200,000 | $ 200,000 |
Note 11 - Share-based Compens_3
Note 11 - Share-based Compensation (Details Textual) - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $ 3,000 | $ 400,000 | $ 144,000 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 1.72 | $ 5.80 | $ 1.33 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,698,452 | ||
Share-based Compensation, Total | $ 2,774,000 | $ 2,707,000 | $ 942,000 |
Employees [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,698,452 | 796,399 | |
Consultants [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 0 | 46,254 | 490,849 |
Non-employees [Member] | |||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 1 year 292 days | ||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options | $ 204,000 | ||
Share-based Compensation, Total | $ 176,000 | $ 768,000 | $ 545,000 |
Employee Stock Option [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | ||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 10 years | ||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 1 year | ||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options | $ 235,000 | ||
Employee Stock Option [Member] | The 2016 Plan [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 7,932,494 | ||
Non-employee Directors and Employees [Member] | |||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $ 5,000,000 | ||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 2 years 146 days | ||
Restricted Stock Units (RSUs) [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 226,471 | ||
Restricted Stock Units (RSUs) [Member] | Non-employee Directors and Employees [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 226,471 |
Note 11 - Share-based Compens_4
Note 11 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Share-based compensation expense | $ 2,774 | $ 2,707 | $ 942 |
Cost of Goods Sold [Member] | |||
Share-based compensation expense | 143 | 140 | 14 |
Research and Development Expense [Member] | |||
Share-based compensation expense | 953 | 678 | 127 |
Selling, General and Administrative Expenses [Member] | |||
Share-based compensation expense | $ 1,678 | $ 1,889 | $ 801 |
Note 11 - Share-based Compens_5
Note 11 - Share-based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Stock options outstanding, beginning of period (in shares) | 4,213,100 | |
Balance, weighted average exercise price, beginning of period (in dollars per share) | $ 2.96 | |
Stock options outstanding, weighted average remaining contractual term (Year) | 7 years 292 days | 8 years 36 days |
Stock options outstanding, aggregate intrinsic value | $ 1,890 | |
Stock options granted (in shares) | 1,698,452 | |
Stock options granted, weighted average exercise price (in dollars per share) | $ 2.41 | |
Stock options exercised (in shares) | (2,488) | |
Stock options exercised, weighted average exercise price (in dollars per share) | $ 1.80 | |
Stock options canceled (in shares) | (431,700) | |
Stock options canceled, weighted average exercise price (in dollars per share) | $ 2.92 | |
Stock options outstanding, end of period (in shares) | 5,477,364 | 4,213,100 |
Balance, weighted average exercise price, end of period (in dollars per share) | $ 2.80 | $ 2.96 |
Exercisable and vested (in shares) | 2,346,990 | |
Exercisable and vested, weighted average exercise price (in dollars per share) | $ 2.72 | |
Exercisable and vested, weighted average remaining contractual term (Year) | 6 years 328 days | |
Exercisable and vested, aggregate intrinsic value |
Note 11 - Share-based Compens_6
Note 11 - Share-based Compensation - Valuation Assumptions for Employee Stock Options (Details) - Employee Stock Option [Member] | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Dividend yield | 0.00% | ||
Expected term (Year) | 6 years 91 days | 6 years 91 days | |
Minimum [Member] | |||
Risk-free interest rate | 2.66% | 1.76% | 1.28% |
Volatility | 81.00% | 81.00% | |
Expected term (Year) | 5 years | ||
Maximum [Member] | |||
Risk-free interest rate | 2.89% | 2.25% | 1.58% |
Volatility | 83.00% | 89.00% | 88.00% |
Dividend yield | 0.00% | 0.00% | |
Expected term (Year) | 6 years 91 days |
Note 11 - Share-based Compens_7
Note 11 - Share-based Compensation - Summary of Non-vested RSUs (Details) - Restricted Stock Units (RSUs) [Member] | 12 Months Ended |
Dec. 31, 2018$ / sharesshares | |
Balance, shares (in shares) | shares | 97,996 |
Balance, weighted average grant date fair value per share (in dollars per share) | $ / shares | $ 8.71 |
RSUs granted, shares (in shares) | shares | 226,471 |
RSUs granted, weighted average grant date fair value per share (in dollars per share) | $ / shares | $ 1.36 |
RSUs vested, shares (in shares) | shares | (57,108) |
RSUs vested, weighted average grant date fair value per share (in dollars per share) | $ / shares | $ 7.03 |
RSUs forfeited, shares (in shares) | shares | |
RSUs forfeited, weighted average grant date fair value per share (in dollars per share) | $ / shares | |
Balance, shares (in shares) | shares | 267,359 |
Balance, weighted average grant date fair value per share (in dollars per share) | $ / shares | $ 2.84 |
Note 11 - Share-based Compens_8
Note 11 - Share-based Compensation - Nonemployee Stock Option Valuation Assumptions (Details) - Non-employee Stock Options [Member] | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Dividend yield | 0.00% | 0.00% | 0.00% |
Minimum [Member] | |||
Risk-free interest rate | 2.80% | 2.25% | 1.60% |
Volatility | 78.00% | 81.00% | 89.00% |
Expected term (Year) | 7 years 219 days | 8 years 219 days | 9 years 219 days |
Maximum [Member] | |||
Risk-free interest rate | 2.95% | 2.40% | 2.42% |
Volatility | 85.00% | 87.00% | 91.00% |
Expected term (Year) | 8 years 292 days | 9 years 292 days | 9 years 328 days |
Note 12 - Concentrations (Detai
Note 12 - Concentrations (Details Textual) - Customer Concentration Risk [Member] | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Sales Revenue, Net [Member] | |||
Concentration Risk, Percentage | 29.00% | ||
Number of Major Customers | 0 | 0 | |
Accounts Receivable [Member] | |||
Concentration Risk, Percentage | 23.00% | 20.00% | 29.00% |
Note 13 - Net Loss Per Share -
Note 13 - Net Loss Per Share - Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Net loss | $ (13,987) | $ (12,308) | $ (10,310) |
Weighted-average shares used in computing net loss per share, basic and diluted (in shares) | 38,377,606 | 38,160,543 | 8,368,284 |
Net loss per share, basic and diluted (in dollars per share) | $ (0.36) | $ (0.32) | $ (1.23) |
Note 13 - Net Loss Per Share _2
Note 13 - Net Loss Per Share - Anti-dilutive Securities (Details) - shares | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Antidilutive securities (in shares) | 8,411,389 | 4,311,096 | 3,491,937 |
Employee Stock Option [Member] | |||
Antidilutive securities (in shares) | 5,477,364 | 4,213,100 | 3,491,937 |
Restricted Stock Units (RSUs) [Member] | |||
Antidilutive securities (in shares) | 267,359 | 97,996 | |
Warrant [Member] | |||
Antidilutive securities (in shares) | 2,666,666 |
Note 14 - Income Taxes (Details
Note 14 - Income Taxes (Details Textual) - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Income Tax Expense (Benefit), Total | $ 0 | $ 0 | $ 0 |
Deferred Tax Liabilities, Net, Total | 0 | 0 | |
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | 3,200,000 | 3,000,000 | |
Unrecognized Tax Benefits that Would Impact Effective Tax Rate | $ 636,000 | $ 511,000 | |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% | 35.00% | |
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | |||
Operating Loss Carryforwards, Total | $ 69,200,000 | ||
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | |||
Tax Credit Carryforward, Amount | 2,000,000 | ||
State and Local Jurisdiction [Member] | |||
Operating Loss Carryforwards, Total | 54,400,000 | ||
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member] | |||
Tax Credit Carryforward, Amount | $ 1,500,000 |
Note 14 - Income Taxes - Effect
Note 14 - Income Taxes - Effective Income Tax Reconciliation (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Tax at federal statutory rate | $ (2,937,000) | $ (4,185,000) | $ (3,505,000) |
State, net of federal benefit | (455,000) | (1,238,000) | (315,000) |
Research and development credit | (236,000) | (135,000) | (89,000) |
Stock-based compensation | 440,000 | 344,000 | 136,000 |
Nondeductible interest | 590,000 | ||
Warrant and derivative revaluation | 328,000 | ||
Change in Federal tax rate | 8,172,000 | ||
Other | 22,000 | 7,000 | 94,000 |
Change in valuation allowance | 3,166,000 | (2,965,000) | 2,761,000 |
Total provision for income taxes | $ 0 | $ 0 | $ 0 |
Note 14 - Income Taxes - Compon
Note 14 - Income Taxes - Components of the Net Deferred Income Tax Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Accrued compensation | $ 84 | $ 110 |
Inventory adjustments | 276 | 449 |
Depreciation and amortization - noncurrent | 113 | 146 |
Share-based compensation | 648 | 558 |
Net operating loss and tax credit carryforwards - noncurrent | 20,698 | 17,368 |
Other | 12 | 34 |
Gross deferred tax asset | 21,831 | 18,665 |
Valuation allowance | (21,831) | (18,665) |
Net deferred tax asset |
Note 14 - Income Taxes - Aggreg
Note 14 - Income Taxes - Aggregate Changes in the Balance of Gross Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Balance, beginning of year | $ 725 | $ 608 |
Additions based on tax positions related to the current year | 166 | 117 |
Additions (reductions) for tax positions related to prior years | ||
Balance, end of year | $ 891 | $ 725 |
Note 16 - Grant Funding (Detail
Note 16 - Grant Funding (Details Textual) - Grant Agreement [Member] - TEDCO [Member] - USD ($) | 1 Months Ended | 12 Months Ended |
Jun. 30, 2016 | Dec. 31, 2018 | |
Grant Funding Available | $ 750,000 | |
Grant Funding, Term of Grant | 3 years | |
Proceeds from Grant Funding | $ 750,000 | |
Research and Development Expense Reduction from Qualified Grant Funding | 105,000 | |
Deferred Revenue from Grants, Current | $ 645,000 |
Note 17 - Related Party Trans_2
Note 17 - Related Party Transactions (Details Textual) - USD ($) | 1 Months Ended | 12 Months Ended | ||
Aug. 31, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,698,452 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ 2.80 | $ 2.96 | ||
Share-based Compensation, Total | $ 2,774,000 | $ 2,707,000 | $ 942,000 | |
OPKO [Member] | Consulting Services [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 418,977 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ 1.80 | |||
Share-based Compensation, Total | $ 142,000 | 480,000 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Grant Date Fair Value | $ 5,300,000 | |||
Consulting Agreement, Term | 4 years | |||
Consulting Agreement, Term, Length of Automatic Renewal Periods | 1 year | |||
Chairman and Chief Executive Officer of OPKO [Member] | ||||
Related Party, Ownership Percentage | 5.00% |
Note 18 - Employee Benefit Pl_2
Note 18 - Employee Benefit Plans (Details Textual) - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent | 75.00% | ||
Defined Contribution Plan, Employer Discretionary Contribution Amount | $ 26,000 | $ 0 | $ 0 |